Tazarotenic acid
目录号: PL01175 纯度: ≥99%
Tazarotenic acid 是 Tazarotene 的代谢产物。Tazarotenic acid 与视黄酸受体 (RAR) 结合是类视黄醇作用的可能分子靶点。Tazarotenic acid 具有疣状角化不良的研究潜力。
CAS No. :118292-41-4
商品编号 规格 价格 会员价 是否有货 数量
PL01175-5mg 5mg ¥1855.00 请登录
PL01175-10mg 10mg ¥3465.00 请登录
PL01175-25mg 25mg ¥8172.50 请登录
PL01175-50mg 50mg ¥14455.00 请登录
PL01175-100mg 100mg 询价 询价
PL01175-200mg 200mg 询价 询价
PL01175-10mM*1mLinDMSO 10mM*1mLinDMSO ¥3182.00 请登录
Medlife所售产品仅用于科学研究(非临床研究),非药品不可食用,不可用于人体或动物的临床诊断和治疗,我们不为个人提供产品及服务。产品COA等资料,可至下方“质量控制”中下载。
中文名称
Tazarotenic acid
中文别名
6-(4,4-二甲基-硫代苯并二氢吡喃-6-基乙炔)-烟酸;6-[2-(3,4-二氢-4,4-二甲基-2H-1-苯并噻喃-6-基)乙炔基]-3-吡啶甲酸;他扎罗汀酸标准品;他扎林酸;他扎罗汀酸 6-[2-(3,4-二氢-4,4-二甲基-2H-1-苯并噻喃-6-基)乙炔基]-3-吡啶甲酸
英文名称
Tazarotenic acid
英文别名
3-Pyridinecarboxylicacid, 6-[2-(3,4-dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl]-;Tazarotenic Acid;6-((4,4-dimethylthiochroman-6-yl)ethynyl)nicotinic acid;6-[2-(4,4-dimethyl-2,3-dihydrothiochromen-6-yl)ethynyl]pyridine-3-carboxylic acid;6-(2-(4,4-Dimethylthiochroman-6-yl)ethynyl)nicotinic acid;6-[2-(3,4-Dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl]-3-pyridinecarboxylic acid;AGN 190299;AGN-190299;Tazarotene acid;6-[[(3,4-Dihydro-4,4-dimethyl-2H-1-benzothiopyran)-6-yl]ethynyl]nicotinic acid;6-[(4,4-diMethyl-3,4-dihydro-2H-thiochroMen-6-yl)ethynyl]pyridine-3-carboxylic acid;6-((3,4-Dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl)-3-pyridinecarboxylic acid;3-Pyridinecarboxylic acid, 6-((3,4-dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl)-;Tazarotene Acid;Tazarotenic acid;6-[2-(3,4-Dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl]-3-pyridine carboxylic acid
Cas No.
118292-41-4
分子式
C19H17NO2S
分子量
323.41
包装储存
Powder -20°C 3 years;4°C 2 years
产品详情
Tazarotenic acid 是 Tazarotene 的代谢产物。Tazarotenic acid 与视黄酸受体 (RAR) 结合是类视黄醇作用的可能分子靶点。Tazarotenic acid 具有疣状角化不良的研究潜力。
生物活性
Tazarotenic acid is the metabolite of Tazarotene. Tazarotenic acid binding to retinoic acid receptors (RARs) is the probable molecular target of retinoid action. Tazarotenic acid has the potential for the research of warty dyskeratoma.
性状
Solid
体内研究(In Vivo)
Assessment of Pharmacokinetics (PK) profile of Tazarotenic acid (Compound AGN 190299) after an intravenous of AGN 190168 in rats
.Male Female
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years;4°C 2 years
参考文献
[1]. Chandraratna RA. Tazarotene--first of a new generation of receptor-selective retinoids. Br J Dermatol. 1996;135 Suppl 49:18-25.
[2]. Hsyu PH, et al. Pharmacokinetics of a novel retinoid AGN 190168 and its metabolite AGN 190299 after intravenous administration of AGN 190168 to rats. Biopharm Drug Dispos. 1994;15(5):347-357.
溶解度数据
In Vitro: DMSO : 100 mg/mL (309.21 mM; Need ultrasonic)配制储备液
搜索质检报告(COA)

1:一般建议:溶解度为Medlife测试数据,可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异,仅做参考,具体以实验方案为准。

2:储存条件:粉末-20°C一般情况可以保存3年,溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异,请细致阅读产品信息,并辅助参考相关文献描述。

The molarity calculator equation
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
The dilution calculator equation
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2